Business
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
LA JOLLA, Calif., March 27, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overall
About this update from Equillium, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/d2dad639f8e59cac86840fd8d62769af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tIryXtERsLGOPljsrlxFYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d2dad639f8e59cac86840fd8d62769af","width":400,"height":400}},"lazy":false},{"type":"text","content":"Treatment with itolizumab did not improve complete or overall response rates at Day 29","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival","length":238,"tagName":"p","attribs":{}},{"type":"text","content":"Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"Management will host a conference call and webcast today at 8:30 am ET","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., March 27, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overall response rate (ORR) at Day 29 between patients treated with itolizumab and placebo; however, statistically significant and clinically meaningful benefit in longer-term outcomes were achieved, including complete response at Day 99, duration of complete response and failure-free survival. Itolizumab exhibited a favorable safety and tolerability profile and did not increase the risk of clinical sequelae, including infection or sepsis, primary drivers of the high mortality associated with aGVHD.","length":1013,"tagName":"p"},{...